📢 #ESMO26 concomitant paper - Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
🔗https://tinyurl.com/3mx946h6
@brian_rini @tompowles1